Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Breakthrough May Revolutionize Preclinical Imaging

By BiotechDaily International staff writers
Posted on 07 Oct 2013
Image: The magnetic particle imaging (MPI) system is an entirely new technology for preclinical imaging (Photo courtesy of Bruker).
Image: The magnetic particle imaging (MPI) system is an entirely new technology for preclinical imaging (Photo courtesy of Bruker).
A novel imaging technique for disease studies, translational research, and drug discovery will soon be made available to the biotechnology research community.

Bruker (Billerica, MA, USA) has announced the world’s first magnetic particle imaging (MPI) system, a novel technology for preclinical imaging. The MPI tomographic imaging technique relies on the detection of the magnetic properties of iron-oxide nanoparticles injected into the bloodstream to produce three-dimensional images. The system has been used to produce images that accurately captured the real-time physiological activity of a mouse's cardiovascular system,

The Bruker preclinical MPI scanner was developed in collaboration with Royal Philips (Amsterdam, The Netherlands), in a partnership that combined Bruker’s leadership in analytical magnetic resonance instruments with Philips’ strengths in medical imaging technology. The partners will co-market the preclinical MPI scanner.

Dr. Michael Heidenreich, technical director at Bruker, said, "We are very pleased about this breakthrough in preclinical imaging and our collaboration with Philips on this exciting technology. Magnetic particle imaging is a novel imaging modality that is expected to enable scientists to address an extensive range of new issues in preclinical research. MPI nicely complements Bruker’s preclinical imaging product portfolio of now nine different modalities. The highly sensitive visualization of functional characteristics in vivo at high temporal resolution offers great potential for small animal imaging, especially when combined with high spatial resolution morphological MRI."

"Magnetic particle imaging represents a fundamentally new imaging modality with an exceptional ability to image in vivo functional behavior," said Homer Pien, chief technology officer at Philips. "We are particularly excited about its potential for providing new insights into cardiovascular disease, cancer, and stem cell therapies. Going forward, I am convinced that the results from the research studies conducted with preclinical MPI systems will provide valuable guidance for our ongoing development of a whole-body clinical MPI system."

Related Links:
Bruker
Royal Philips


comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Alternative splicing produces two protein isoforms (Photo courtesy of Wikimedia Commons).

Key Regulator of Cancer-Inducing Alternative Splicing Identified

Cancer researchers have identified the splicing factor RBM4 (RNA-binding protein 4) as a key determinant in processes that prevent tumor development and spread. RBM4 is known to be crucial to gene splicing... Read more

Drug Discovery

view channel

Ibuprofen May Restore Immune Function in Older Individuals

New research suggests that macrophages from the lungs of old mice respond differently to infections than those of young mice, and ibuprofen given to the mice reversed these changes. New research using lab mice suggests that the solution to more youthful immune function might already be a common over-the-counter pain reliever.... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.